Three questions with BioAffinity CEO Maria Zannes
OCTOBER 23, 2015
As published in the San Antonio Business Journal
By W. Scott Bailey
San Antonio Business Journal
San Antonio’s bioAffinity Technologies was invited to present its novel technology for the detection and diagnosis of early-stage lung cancer at the 2015 Pharmaceutical/Medtech Dealmaking Symposium in Chicago last week. bioAffinity President and CEO Maria Zannes said her organization was one of eight early-stage companies in the U.S. selected to participate in the event. She discussed with the Business Journal the impact the presentation could have on bioAffinity, which is seeking to raise $15 million, and on San Antonio’s bioscience industry.
Roughly how many investors were present?
The event gathered together about 100 bankers, investment firms, strategists and professionals from across the deal-making spectrum. Each had an interest in early-stage companies in the health care market, and a focus on medical devices, drug delivery and pharmaceuticals.
How might your presence at the event impact future fundraising opportunities?
Every fundraising event presents challenges, with one of the biggest being able to get your story out to the investment community. The Chicago event most certainly will help with fundraising by getting key people talking. It also gave us the opportunity to highlight San Antonio and our collaborative research with The University of Texas Health Science Center. Investors also were interested in the UTSA Commercialization program that is supporting bioAffinity Technologies by offering collaboration with its researchers and use of laboratory space.
Do you expect that bioAffinity will land new investor support as a result of its presentation in Chicago?
Our success with the Series A round will be the result of events such as the Chicago symposium, as well as a very aggressive push with sophisticated investors in major business centers like New York. We also are talking to strategic investors who eventually could acquire us.